←Back to Expert Scholars
Translational Medicine / 转化医学Pembrolizumab Clinical Development
Roy Baynes
MBBCh, PhD
🏢Merck Research Laboratories🌐USA
Former Senior Vice President and Head of Global Clinical Development
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Roy Baynes led the global clinical development of pembrolizumab at Merck, overseeing the KEYNOTE program that generated approvals across more than twenty cancer indications. His leadership shaped the evidentiary standards for PD-1 therapy across solid and hematologic malignancies.
Share:
🧪Research Fields 研究领域
pembrolizumab development
KEYNOTE program
immune checkpoint trials
PD-1 inhibitors
oncology regulatory
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Roy Baynes 的研究动态
Follow Roy Baynes's research updates
留下邮箱，当我们发布与 Roy Baynes（Merck Research Laboratories）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment